Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash from Investing Activities for 8 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 393750.0% to -$7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.9 million, a 23918.18% decrease, with the full-year FY2025 number at -$7.9 million, down 23918.18% from a year prior.
  • Cash from Investing Activities was -$7.9 million for Q4 2025 at Akebia Therapeutics, down from -$77000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $20.0 million in Q2 2021 to a low of -$7.9 million in Q4 2025.
  • A 4-year average of $3.2 million and a median of -$15500.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 8039.18% in 2021, then tumbled 393750.0% in 2025.
  • Akebia Therapeutics' Cash from Investing Activities stood at $20.0 million in 2021, then crashed by 100.57% to -$114000.0 in 2022, then skyrocketed by 98.25% to -$2000.0 in 2024, then crashed by 393750.0% to -$7.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cash from Investing Activities are -$7.9 million (Q4 2025), -$77000.0 (Q3 2025), and -$126000.0 (Q2 2025).